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Abstract
Background: Epithelial- to- mesenchymal transition (EMT) plays a pivotal role in 
resistance to EGFR tyrosine kinase inhibitors (TKIs) in non- small- cell lung cancer 
(NSCLC). Our previous study revealed that in osteosarcoma, human apurinic/apy-
rimidinic endonuclease 1 (APE1) regulates transforming growth factor- β (TGF- β), 
an important player in EMT. We therefore hypothesized a link between APE1 and 
EGFR- TKI responsiveness in NSCLC.
Methods: The protein levels of APE1 were analyzed in tumors of NSCLC patients 
receiving EGFR- TKI treatment. The correlation between APE1 expression and 
progression- free survival (PFS), overall survival (OS), or response rate were ana-
lyzed. The impact of APE1 on the response to EGFR- TKIs was measured by exog-
enous manipulation of APE1 in EGFR- TKI- sensitive and EGFR- TKI- resistant cells.
Results: We indicate that low expression of APE1 in tumors is associated with a 
significantly longer PFS (20.8 months vs 8.4 months, P = 0.008) and a preferential 
OS (39.0 months vs 17.0 months, P = 0.001), with no difference in initial response 
rate to EGFR- TKIs. We observed that APE1 protein level was significantly increased 
in EGFR- TKI- resistant cells and was associated with downregulated E- cadherin and 
upregulated vimentin. The EMT phenotype, as well as the levels of TGF- β, was sup-
pressed in APE1 knockdown HCC827/IR and PC- 9/ER cells, while the EMT pheno-
type was promoted in APE1- overexpressed HCC827 and PC- 9 cells. Furthermore, a 
specific APE1 redox inhibitor (ie, E3330) effectively reversed the EMT phenotype 
and further sensitized the cells to EGFR- TKIs.
Conclusion: This study revealed a significant role of APE1 in EGFR- TKI resistance 
via novel regulatory effects on the EMT phenotype in NSCLC.
K E Y W O R D S
apurinic/apyrimidinic endonuclease 1, EGFR-TKI resistance, epithelial-to-mesenchymal transition, 
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1 |  INTRODUCTION
The introduction of EGFR tyrosine kinase inhibitors (EGFR- 
TKIs), including gefitinib, erlotinib, and icotinib,1 has success-
fully improved the response rate, progression- free survival, 
and overall survival of advanced non- small- cell lung cancer 
(NSCLC) patients from <1 year to up to 3.5 years in patients car-
rying driver gene mutations. Oral administration of EGFR- TKIs 
is now a standard first- line treatment for NSCLC patients with 
activating EGFR mutations, such as exon 19 deletions and the 
L858R point mutation. Unfortunately, patients with a promising 
initial response rate (~75%) usually develop acquired resistance 
to EGFR- TKIs within 8- 10 months, which limits continuous 
clinical benefit. Optimal treatment after progression is not clearly 
defined. Collective efforts have been made to understand the 
mechanisms of resistance to EGFR- TKIs in order to overcome 
or, at least, attenuate the development of acquired resistance. 
Although secondary mutations, such as the T790M gatekeeper 
mutation in the EGFR tyrosine kinase domain, account for half 
of the resistance to first- generation EGFR- TKIs, the remaining 
mechanisms and key players are not yet understood.
During the process of acquired EGFR- TKI resistance of 
NSCLC, the epithelial- to- mesenchymal transition (EMT) 
program is considered to be activated, as shown in recent 
clinical studies.2-5 For instance, Sequist et al3 analyzed biopsy 
samples from 37 cases of drug- resistant NSCLC patients car-
rying EGFR mutations, and a pronounced EMT was observed 
in a subset of EGFR- TKI- resistant specimens. In agreement 
with these findings in clinical specimens, NSCLC cell lines 
with activating EGFR mutations may develop an EMT phe-
notype upon long- term exposure to erlotinib or gefitinib.6,7 
EMT is a cellular program characterized by loss of an epithe-
lial gene expression signature, such as E- cadherin, and gain 
of activation of genes that partially define mesenchymal fea-
tures, such as vimentin. EMT is observed in normal develop-
ment and associated with enhanced invasiveness, metastatic 
behavior, and EGFR- TKI resistance of epithelial cancers. The 
importance of EMT in EGFR- TKI resistance is highlighted 
by the observations of Chung et al4 that EMT developed in 
a lung cancer patient who had an acquired resistance to erlo-
tinib, while there were no known resistance mechanisms such 
as a T790M mutation or MET amplification. This observation 
suggests that the activation of EMT could independently trig-
ger EGFR- TKI resistance. However, the detailed regulatory 
mechanisms of EMT are just beginning to be understood.
Alterations of the gene expression profile during EMT, as 
well as nontranscriptional changes, are regulated by the con-
vergence of signaling pathways that respond to extracellular 
stimuli. Among these, transforming growth factor- β (TGFβ) 
signaling plays a predominant role in inducing EMT. In car-
cinomas, activation of the TGFβ1 signaling pathway pro-
motes an epithelial plasticity response, which further triggers 
EMT. It is now known that TGFβ1 promotes EMT through 
Smad- dependent transcriptional regulation of HMGA2, which 
further induces expression of the important EMT- associated 
transcription factors Snail, Slug, and Twist.8 Our previous re-
port showed that human apurinic/apyrimidinic endonuclease 
1 (APE1) promotes transcriptional activation of TGFβ1 ex-
pression in osteosarcoma cells.9 We have clearly shown that 
APE1 knockdown downregulated TGFβ1 mRNA, intracel-
lular protein, and secretion levels, which further attenuated 
in vitro angiogenesis. As osteosarcoma is a mesenchymal- 
derived malignancy, we were unable to observe the epithelial 
plasticity or EMT phenotype, but we hypothesized that APE1 
could contribute to regulation of EMT in epithelial can-
cers. However, to our knowledge, there is no direct evidence 
demonstrating the association of APE1 with EMT.
APE1 is an essential enzyme in DNA base excision repair 
(BER), which primarily repairs oxidative lesions and alkylation 
of bases as well as spontaneous hydrolysis of bases. More impor-
tantly, the APE1 protein contains reduction- oxidation (redox)- 
sensitive cysteine residues, which respond to redox alterations 
in the microenvironment, which in turn alters the DNA bind-
ing activities of transcription factors, including AP- 1, NF- κB, 
p53, HIF- 1α, and NRF- 1.10 Considering the downstream tar-
get genes that these transcription factors regulate, APE1 plays 
a fundamental role in the cellular response to oxidative stress 
and other redox- related stimuli. There is an increasing body of 
evidence showing that EMT is also a redox- responsive process 
and that the critical transcription factor Snail is regulated by 
ROS production (reviewed in 11). Thus, it is reasonable to hy-
pothesize that APE1 may participate in an EMT process, based 
on the redox responsiveness of EMT and our previous exper-
imental data on TGFβ1 regulation. Therefore, in our current 
study, we investigated the relationship existing between APE1 
expression and EGFR- TKI acquired resistance mediated by 
EMT activation in NSCLC biopsy tissue. In addition, we also 
analyzed this relationship in established EGFR- TKI- resistant 
cell lines. The study was designed to elucidate how APE1 af-
fects the expression of specific epithelial and mesenchymal tis-
sue markers in the EMT process and which function of APE1 
is responsible for this effect. Furthermore, we tested whether 
the APE1 inhibitors may restore responsiveness to EGFR- TKIs 
in the acquired resistant cell lines via inhibition of EMT. This 
study, to the best of our knowledge, shows the first evidence 
confirming the role of APE1 in EGFR- TKI resistance via pro-
moting EMT and further highlights the therapeutic potential of 
APE1 inhibitors to decrease EGFR- TKI resistance.
2 |  MATERIALS AND METHODS
2.1 | Study subjects
The study group consisted of 101 advanced NSCLC pa-
tients (48 male and 53 female, mean age 59.5 years) either 
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carrying an activating EGFR gene mutation or with unknown 
EGFR gene status but with potential benefit from EGFR- 
TKIs.12 All patients were from the Chinese Han population 
and consecutively enrolled from January 2011 to December 
2013 in Daping Hospital, Third Military Medical University 
(Chongqing, China), without restriction of age, gender, pa-
thology, or stage. All patients received standard first- line 
administration of gefitinib, erlotinib, and icotinib without 
any chemotherapy or localized treatment. At recruitment, in-
formed consent was obtained from each patient, and each par-
ticipant was then interviewed to solicit detailed information 
on demographic characteristics. This study was approved by 
the ethics committee of Daping Hospital. All patients were 
followed up for more than 36 months.
2.2 | Cell culture and human tissue samples
Human lung adenocarcinoma cell line HCC827, carrying the 
EGFR gene exon 19 deletion, and its in vitro induced icotinib- 
resistant derivate HCC827/IR were obtained from the R&D 
Department of Betta Pharmaceuticals Co., Ltd.13 Another 
human lung adenocarcinoma cell line PC- 9, carrying the EGFR 
gene exon 19 deletion, and its in vitro induced erlotinib- resistant 
derivate PC- 9/ER were kind gifts from Dr. Bo Zhu from 
Xinqiao Hospital, Third Military Medical University. HCC827 
and HCC827/IR cells were grown in RPMI- 1640 (HyClone 
Laboratories Inc., LOGAN, UT, USA) supplemented with 10% 
FBS, while PC- 9/ER, as well as their parental sensitive cells, 
were cultured in DMEM (HyClone) with 10% FBS.
2.3 | Targeted genomic capture and next- 
generation sequencing (NGS)
The NGS assays of HCC827/IR and PC- 9/ER cells were car-
ried out in facility of MyGenostics biotech company (Beijing, 
China). Whole- exon regions of the target genes were enriched 
using the MyGenostics Target Region Enrichment protocol. 
Three micrograms of genomic DNA were fragmented by 
nebulization and repaired. Illumina adapters were then ligated 
to the fragments, and the final size was 350- 400 bp. The en-
richment libraries were sequenced on Illumina HiSeq 2000 se-
quencer for paired read 100 bp. Next, high- quality reads were 
identified using SOAPaligner software, respectively. Variants 
were first selected using SOAPsnp software,14 and then, they 
were further processed according to the dbSNP (v130) data-
base and CCDS. Subsequently, the reads were realigned to the 
reference genome (NCBI36.3) using BWA software.15 SNPs 
and indels were identified using GATK programs.
2.4 | APE1 overexpression and knockdown
For exogenous overexpression of APE1, cultured cells were 
transfected with an APE1 eukaryotic expression vector, 
p3XFLAG- CMV/APE1WT16 or control empty backbone vec-
tor using X- tremeGENE 9 DNA Transfection Reagent (Roche 
Diagnostics, Shanghai, China) following the manufacturer’s 
protocol. Cells were then cultured for another 72 hours before 
protein expression level determination or phenotype meas-
urements. For APE1 knockdown experiments, cells were 
transfected with 0.2 nmol/L APE1- siRNA; the sequences for 
APE1- siRNA1: 5′- UACUCCAGUCGUACCAGACCU- 3′, 
5′- GUCUGGUACGACUGGAGUACC- 3′, APE1- siRNA2: 
5′- CUCAAUGUGGCACAUGAAG- 3′, 5′- CUUCAUGUGC 
CACAUUGAG- 3′, and for scramble- siRNA: 5′- GACCAU 
GCUGACCUCAUGGAA- 3′, 5′- CCAUGAGGUCAGCAU 
GGUCUG- 3′. These siRNAs were transfected with 
Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) ac-
cording to the manufacturer’s instructions. After 48 hours, 
the cells were harvested for protein expression level determi-
nation or phenotype measurements.
2.5 | Cell viability assay
Cell viability was determined after drug treatments with/
without APE1 manipulation using the cell counting kit- 8 
(CCK- 8, Beyotime Inst. Biotech, China) according to the 
manufacturer’s instructions.
2.6 | Western blot analysis and antibodies
For whole- cell extracts, cells were washed with ice- cold 
phosphate- buffered saline and collected by scraping. Cell 
pellets were homogenized in extraction buffer (50 mmol/L 
Tris- HCl, 0.1% sodium dodecyl sulfate [SDS], 150 mmol/L 
NaCl, 100 μg/mL phenylmethylsulfonyl fluoride, 1 μg/mL 
aprotinin, 1% nonidet P- 40, and 0.5% sodium orthovana-
date), then incubated at 4°C for 20 minutes, and centrifuged 
for 20 minutes at 12 000 g. The protein levels in the extracts 
were quantified using the Bio- Rad DC protein assay. For 
Western blotting, whole- cell extracts (20 μg/lane) were re-
solved on 8%- 12% SDS- polyacrylamide gels and transferred 
onto nitrocellulose membrane (0.45 μm; Millipore, Bedford, 
MA, USA) in 25 mmol/L Tris- base, 190 mmol/L glycine, 
and 20% methanol using a semidry blotter. Membranes were 
blocked with 8% fat- free milk and 0.1% Tween 20 in Tris- 
buffered saline. The APE1 monoclonal antibody was diluted 
1:3000 while the E- cadherin (Abcam, Shanghai, China) and 
vimentin (Cell Signaling Technology, Shanghai, China) 
monoclonal antibodies were used at the 1:1000 dilution rec-
ommended by the suppliers. The membranes were then in-
cubated with a horseradish peroxidase- conjugated secondary 
antibody (1:2000) (Pierce, Rockford, IL, USA). The proteins 
were detected using an enhanced chemiluminescence detec-
tion system (Pierce), and light emission was captured on X- 
ray films (Kodak, Rochester, NY, USA).
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2.7 | Immunofluorescent staining
Cells growing on the chamber slides for attachment were 
subjected to various treatment before fixation using 4% para-
formamide/PBS (w/v) at room temperature for 15 minutes. 
Cells were incubated with permeabilizing solution (0.1% 
Triton X- 100 in PBS, v/v) for 5 minutes. Cells were then 
blocked with 1% BSA at RT for 1 hour followed by over-
night incubation with primary antibodies at 4°C in a humidity 
chamber. On the next day, the cells were washed with PBST 
for 15 minutes on a rocking board and then incubated with 
secondary antibodies (1:200 dilution) for 1 hour at room tem-
perature. After washing with PBST, cells were incubated with 
DAPI for 5 minutes to stain the nuclei. Finally, cells were 
mounted with antifade mounting medium and images were 
captured using a LSCM laser scanning confocal microscope).
2.8 | Enzyme- linked immunosorbent assay 
(ELISA)
The 24- hour cell- free supernatant of tissue culture from 
PC- 9 with or without APE1 overexpression and PC- 9/ER 
with or without APE1 knockdown were collected 48 hours 
post- transfection or infection and measured using a TGF- β1 
ELISA kit (Invitrogen) following the manufacturer’s instruc-
tion. The absorbance of each well was read at 450 nm.
2.9 | Electrophoretic mobility shift assay 
(EMSA)
EMSA was performed according to the LightShift 
chemiluminescence EMSA kit with minor modifica-
tions. Briefly, the nuclear extracts were incubated with 
3′- biotin- labeled single- stranded telomeric DNA probes. 
The probes containing the STAT3 consensus (STAT3F, 
5′- GATCCTTCTGGGAATTCCTAGATC- 3′, and 
STAT3R, 3′- CTAGGAAGACCCTTAAGGATCTAG- 5′) 
or the HIF- 1α consensus (HIF- 1αF, 5′- TCTGTACGTG 
ACCACACTCACCTC- 3′, and HIF- 1αR, 3′- AGACATGC 
ACTGGTGTGA GTGGAG- 5′) were synthesized (Beyotime, 
Shanghai, China). After incubation, the samples were sepa-
rated on a 5% polyacrylamide gel at 100 V for 60 minutes 
and then transferred to a Zeta- Probe GT nylon membrane 
(Bio- Rad). The probes were detected by HRP- conjugated 
streptavidin and visualized by ECL reagents provided with 
the kit. The bands were quantified by Quantity One imaging 
software (Bio- Rad, Hercules, CA, USA).
2.10 | In vivo experiments
Male BALB/c nude mice between 4 and 5 weeks old 
were used for this study. Cell suspensions of HCC827/IR 
(1 × 106) were inoculated subcutaneously to both groins of 
each nude mouse (20 mice in total). When the xenografts 
grew to approximately 250 mm3 on day 9 after cell inocula-
tion, 18 tumor- bearing mice were randomized into either the 
control group, icotinib group or E3330 + icotinib group (six 
mice per group). Icotinib (70 mg/kg) was injected abdomi-
nally once a day in the icotinib group, while E3330 (25 mg/
kg) and icotinib (70 mg/kg) were injected abdominally once 
a day in the E3330 + icotinib group. After 12 days of con-
tinuous administration, the nude mice were sacrificed, and 
histologically, intact tumor tissues were collected. Tumor 
sizes were measured before each treatment and after the 
mice were sacrificed and calculated according to the for-
mula: tumor size (mm3) = (maximum diameter ×minimum 
diameter2)/2.
2.11 | Immunohistochemistry
Sections from paraffin- embedded tumors were incubated 
with the indicated EMT marker antibodies overnight at 4°C 
and then rinsed with PBS and incubated with secondary an-
tibody. Sections were rinsed with PBS and developed with 
diaminobenzidine substrate, and then counterstained with 
diluted Harris hematoxylin. Positive staining was detected 
as a brown color of the cells. A random 10 high power 
fields or at least 1000 tumor cells were counted and graded 
as follows: negative (−): positive cells rate <10%; posi-
tive (+): positive cells rate ≥10%; positive (++): positive 
cells rate ≥30%; positive (+++): positive cells rate ≥60%. 
Negative (−) and positive (+) were defined as low expres-
sion, while positive (++) and (+++) were defined as high 
expression.
2.12 | Statistical analysis
All continuous data were expressed as the mean ± SD. 
Statistical analysis of numerical variables was assessed using 
the Student’s t test and one- way ANOVA, while the cate-
gorical variables were performed with chi- square test. The 
univariate survival analysis was conducted by log- rank test, 
and the multivariate one was conducted by COX hazard re-
gression analysis. All statistical performance was achieved 
through SPSS 13.0. Differences with P < 0.05 were consid-
ered as statistically significant.
3 |  RESULTS
3.1 | Overexpression of APE1 is associated 
with EGFR- TKI resistance in NSCLC patients 
carrying activating EGFR mutants
To correlate APE1 protein levels in the tumors of NSCLC 
patients with their responses to first- generation EGFR- TKIs, 
the expression of APE1 protein was analyzed in biopsy tissue 
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by IHC. The analysis was performed on a cohort of 101 ad-
vanced NSCLC patients either carrying an activating EGFR 
gene mutation or with unknown EGFR gene status but with 
potential benefit from EGFR- TKIs.12 All patients received 
standard first- line administration of gefitinib, erlotinib, and 
icotinib without any chemotherapy or localized treatment. 
The clinicopathological characteristics are summarized 
in Table 1. Kaplan- Meier survival curves show that low- 
expression of APE1 is associated with an attenuated resistance 
represented by a significantly longer PFS (20.8 months vs 
8.4 months, P = 0.008), while eventually reflecting a benefit 
on the overall survival (OS) (39.0 months vs 17.0 months, 
P = 0.001) (Figure 1). We also evaluate the association be-
tween APE1 expression and survival through COX hazard 
regression model (likelihood ration forward test), which 
shows that APE1 could be an independent negative factor 
for both PFS and OS (Table 2). The patients with high APE1 
expression have a shorter PFS and OS, compared with those 
with low APE1 expression. These results imply that APE1 
might play an important role in initiating or promoting resist-
ance to EGFR- TKIs in NSCLC, while its mechanism remains 
unclear.
3.2 | APE1 level is elevated in EGFR- 
TKI- resistant cell lines and regulates cellular 
responses to EGFR- TKIs
To explore the role of APE1 in the cellular response to 
EGFR- TKI, APE1 protein levels following EGFR- TKI 
treatment were initially determined in NSCLC cells. 
To distinguish the different responses in EGFR- TKI- 
sensitive and EGFR- TKI- resistant cells, two established, 
acquired resistant cell lines, HCC827/IR and PC- 9/ER, 
as well as their parental sensitive cells were utilized (the 
resistant features are examined by CCK- 8 and shown in 
Figure 2A,B). We detected no T790M mutation, MET 
amplification or other known resistant- related gene altera-
tion in both TKI- resistant cell lines by NGS. As shown 
in Figure 2C,D, basal APE1 protein levels are signifi-
cantly increased to more than 10- fold in both resistant 
cell lines when compared to their parental cells. Though 
APE1 downregulated in response to EGFR- TKI in sen-
sitive cells at 48 hours probably is due to cell death, we 
can still see a veritable response to EGFR- TKIs at both 12 
and 24 hours (P < 0.01), but not in resistant cells, suggest-
ing that the compromised APE1 expression facilitates the 
cytotoxicity of EGFR- TKIs while high APE1 level con-
fers resistance (Figure 2E- G). To test this hypothesis, we 
determine the cytotoxicity of EGFR- TKIs using a CCK8 
assay after exogenous manipulation of APE1 expression. 
APE1 was successfully knocked down in HCC827/IR and 
PC- 9/ER cell lines via siRNA transfection and overex-
pressed in HCC827 and PC- 9 via lentiviral particles, both 
confirmed by Western blot. The gefitinib IC50 in APE1 
overexpressing HCC827 and PC- 9 cells is increased com-
pared to control lentiviral particle- infected cells demon-
strating increased resistance to EGFR- TKIs (P < 0.01) 
(Figure 3A,B). Meanwhile, APE1 knockdown in resist-
ant cell lines significantly sensitizes the cells to EGFR- 
TKIs (P < 0.01) (Figure 3C,D), which further confirms 
that APE1 plays an important role in regulating cellular 
response and sensitivity to EGFR- TKI treatment.
T A B L E  1  Clinicopathological characteristics of patients
Characteristics Number of patients Percentage
Age
Average ± SD 59.48 ± 11.82
<60 56 55.45
≥60 45 44.55
Gender
Male 48 47.52
Female 53 52.48
Pathology
Squamous cell 
carcinoma
5 4.95
Adenocarcinoma 88 87.13
Other 8 7.92
Stagea
I+II 1 1.39
III+IV 71 98.61
Drug
Gefitinib 44 43.56
Erlotinib 51 50.50
Icotinib 6 5.94
Response
CR 2 1.98
PR 54 53.47
SD 31 30.69
PD 14 13.86
Smoking statusb
Smoker 75 76.53
Nonsmoker 23 23.47
EGFR mutationc
Positive 67 94.37
Negative 4 5.63
APE1 expression
High expression 72 71.29
Low expression 29 28.71
aTwenty- nine subjects were unable to evaluate exact stage.
bTwo subjects were unable to confirm whether they ever smoked.
cThirty subjects were unable to evaluate the mutation condition of EGFR.
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3.3 | APE1 is associated with the EMT 
process in NSCLC cells
Epithelial- to- mesenchymal transition has been considered 
one of the most important mechanisms of tumor progres-
sion. Therefore, we confirm that EMT occurs in two EGFR- 
TKI- resistant cell lines by analyzing the epithelial marker 
E- cadherin and the mesenchymal marker vimentin using 
Western blot assay (Figure 4A). To test if APE1 is involved 
in the EMT process during the development of acquired re-
sistance to EGFR- TKIs, EMT markers are checked in both 
the APE1 overexpressing EGFR- TKI- sensitive cells and 
APE1 knockdown EGFR- TKI- resistant cells. As shown in 
Figures 4E and S1B, overexpressing APE1 in EGFR- TKI- 
sensitive cells, where APE1 is minimally expressed, produces 
an EMT- like phenotype including a transition in morphology 
involving E- cadherin downregulation and vimentin upregula-
tion. On the other hand, when APE1 expression is knocked 
down in EGFR- TKI- resistant cells where EMT has occurred, 
the epithelial phenotype is restored (Figures 4D and S1A). The 
EMT markers in NSCLC cells with varying APE1 expression 
status are further confirmed morphologically via phase con-
trast microscope and immunofluorescence (Figure 4B,C). The 
results demonstrate that a low- expression level of APE1 is 
important in maintaining the epithelial phenotype in EGFR- 
TKI- sensitive cells, while elevated APE1 facilitates EMT 
F I G U R E  1  Association of APE1 protein level in NSCLC tissue and PFS and OS of patients receiving EGFR- TKI. The expression of 
APE1 protein from 101 advanced NSCLC patients either carrying an activating EGFR gene mutation or with unknown EGFR gene status but 
with potential benefit from EGFR- TKI was determined in biopsy tissue by IHC assay. The PFS (A) and OS (B) comparisons between different 
expression levels of APE1 were indicated in the Kaplan- Meier survival curves, and the P value of each comparison was shown at the left corner
Characteristics
PFS OS
HR (95%CI) P value HR (95%CI) P value
Age 0.429 0.841
Gender 0.254 0.855
Pathology 2.090(1.068- 4.089) 0.031* 2.588(1.275- 5.253) 0.008*
Stagea 0.614 0.722
Drug 0.449 0.461(0.240- 0.888) 0.020*
Smoking statusb 0.334 0.700
EGFR mutationc 0.946 0.487
APE1 expression 2.998(1.229- 7.314) 0.016* 4.724(1.564- 14.267) 0.006*
aTwenty- nine subjects were unable to evaluate exact stage.
bTwo subjects were unable to confirm whether they ever smoked.
cThirty subjects were unable to evaluate the mutation condition of EGFR.
*P < 0.05
T A B L E  2  Multivariant analysis for 
PFS and OS of patients
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during the development of acquired resistance to EGFR- TKIs 
in NSCLC.
3.4 | APE1 regulates EMT through 
TGF- β signaling
TGF- β signaling plays a core regulatory role in the EMT 
process, and we previously demonstrated that APE1 pro-
motes TGF- β transcription in osteosarcoma, a malignancy 
derived from mesenchymal tissue.9 To further confirm this 
regulatory relationship in NSCLC epithelial cancer, TGF- β 
secretion from cancer cells was evaluated by ELISA. We 
initially showed that TGF- β secretion is significantly el-
evated in EGFR- TKI- resistant cell lines (Figure 5A). 
Conditioned medium was obtained from PC- 9 cells, with or 
without overexpression of APE1, and from PC- 9/ER with or 
without knockdown of APE1, upon culturing for 24- hours 
in vitro and collected at 48 hours post- transfection or in-
fection. ELISA data shows that TGF- β secretion is down-
regulated in APE1 knockdown cells compared to scrambled 
shRNA infected PC- 9/ER cells, whereas TGF- β secretion 
is upregulated in APE1 overexpressing cells (Figure 5B,C). 
These results, in agreement with the EMT alteration pat-
tern, strongly suggested that the influence of APE1 on EMT 
could be exerted through its control of TGF- β in both epi-
thelial and mesenchymal cancers. The rescue experiments 
were carried out by adding recombinant TGF- β protein to 
the culture media of APE1 knockdown PC- 9/ER cells at a 
F I G U R E  2  APE1 level elevated 
in EGFR- TKI- resistant cell lines. Two 
established acquired resistant cell lines, 
HCC827/IR and PC- 9/ER, as well as their 
parental EGFR- TKI responsive cells, were 
subjected to CCK8 assay to determine 
the responsiveness of different cells to 
increasing concentrations of gefitinib (A 
and B), * indicates statistically significant 
difference when compared with the same 
treatment dose of parental cell (P < 0.01). 
HCC827/IR and PC- 9/ER cells, as well 
as their parental EGFR- TKI- responsive 
cells, were treated with 20 nmol/L gefitinib 
(representative blots shown in C and D) for 
48 h or with increasing concentrations of 
gefitinib (representative blots shown in E), 
harvested, and analyzed by Western blot 
for APE1 protein levels. APE1 expression 
levels were assayed by Western blot in 
EGFR- TKI- resistant HCC827/IR and PC- 
9/ER, as well as their parental cells (F and 
G, respectively), * indicates a statistically 
significant difference when compared with 
the DMSO treated cells (P < 0.01). The 
mean values of at least three individual 
repeated experiments are shown as the 
mean ± SD
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final concentration of 5 ng/mL. As a result of TGF- β addi-
tion, APE1 knockdown PC- 9/ER cells regained resistance 
to gefitinib (P < 0.01), which was measured by CCK- 8 
assay (Figure 5D). Taken together, our current data demon-
strate that APE1 promotes EGFR- TKI resistance in NSCLC 
cells by facilitating EMT, which is mediated by its control 
of TGF- β expression.
3.5 | The APE1 redox inhibitor E3330 
suppresses EMT and restores the responsiveness 
to EGFR- TKIs in vitro and in vivo
To evaluate if it is clinically feasible to utilize APE1 in-
hibitors to restore the responsiveness to EGFR- TKIs in 
patients with acquired resistance, two activity- specific 
inhibitors, including inhibitor III,17 which is specific for the 
endonuclease activity on abasic DNA, and E3330,18 which 
is specific for redox activity, were introduced. As shown 
in Figure 6A,B, E3330 significantly restores sensitivity 
to gefitinib in HCC827/IR and PC- 9/ER cells (P < 0.01) 
when compared to inhibitor III and vehicle (DMSO). As 
previously documented, treatment using these inhibitors 
had similar effects as compared to introducing individual 
functional mutants of APE1.19 These results suggest that 
APE1 redox activity, rather than DNA repair activity, is 
involved in EGFR- TKI resistance and that this redox ac-
tivity controls the EMT process. Then, we analyzed the 
EMT markers by Western blot in cells treated with either 
one or the other inhibitor and found that the epithelial phe-
notype was reversed in E3330- treated cells but not in cells 
F I G U R E  3  Manipulations of APE1 
regulate cellular responses to EGFR- TKIs. 
APE1 was overexpressed in HCC827 and 
PC- 9 cell lines via lentiviral particles (A 
and B) and knocked down in HCC827/IR 
and PC- 9/ER via two different siRNA 
sequences specific for the Ape1 gene (C 
and D). APE1 expression levels were then 
analyzed by Western blot (shown in the 
upper panel of each subfigure) and treated 
with increasing concentrations of gefitinib 
to determine the cytotoxicity of EGFR- TKI 
by CCK8 assay. To exclude the impact of 
APE1 manipulation on cell growth, various 
gefitinib dose treatments of each group have 
been normalized to the readout of 0 uM 
(DMSO only) treatment. Mean values of at 
least three individual experimental repeats 
are shown as the mean ± SD. In A and B, 
statistically significant differences of the 
APE1 overexpression group when compared 
with empty particle- infected parental 
sensitive cells (indicated by *) or resistant 
cells (indicated by #) at the same treatment 
dose/time (P < 0.01) are shown. In C and 
D, statistically significant differences of 
APE1 knockdown group when compared 
with empty particle- infected resistant cells 
(indicated by *) or parental sensitive cells 
(indicated by #) at the same treatment dose/
time are shown (P < 0.01)
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treated with inhibitor III (Figures 6C and S2). These data 
further confirm and are consistent with the premise that 
APE1 redox activity is the key functional component ex-
erting a regulatory effect on EMT and subsequent EGFR- 
TKI resistance.
We further investigated whether the in vitro restoration 
of EGFR- TKI responsiveness by E3330 could be repeated in 
xenograft models in vivo. As an equivalent alternative to ge-
fitinib, we utilized the first- generation EGFR- TKI, icotinib, 
which has been clinically proven to be equivalent to gefi-
tinib.1,20 HCC827/IR cells were injected into nude mice and 
treated when the xenograft volume reached approximately 
250 mm3 with icotinib or icotinib combined with E3330 or 
vehicle alone for 12 days, as the nude mice cannot tolerate 
tumor load for a longer time. The growth of xenografts in the 
three groups was monitored and shown in Figure 7A. The re-
sult, in agreement with in vitro data, suggests that E3330, in 
combination with EGFR- TKI, suppresses EGFR- TKI- resistant 
cancer cell growth (P < 0.01), whereas the tumor continues 
vigorously growing in the EGFR- TKI alone treated group and 
vehicle control group. To confirm that the EMT process can 
be reversed in the E3330- treated group in vivo, a Western blot 
assay on xenograft extracts (Figure 7B) and an IHC assay on 
tissue slides (Figure 7C) were performed to show the change 
of EMT biomarkers in all three groups. The data shown in 
Figure 7B suggests that E3330- treatment upregulates the ep-
ithelial marker in HCC827/IR cells without interfering with 
APE1 expression level. We noted that icotinib treatment 
slightly downregulates vimentin expression without inducing 
E- cadherin expression. IHC results agree with Western blot 
results showing that E3330 in combination with icotinib treat-
ment significantly upregulates E- cadherin expression while 
decreasing vimentin expression. Icotinib treatment alone has 
no significant effects on either EMT marker, suggesting that 
E3330 could, at least, partially reverses the EMT phenotype 
in HCC827/IR cells, which is in agreement with in vitro ex-
periments. Considering APE1 expression is not affected by 
E3330/Icotinib combinational treatment, these results provide 
support for the hypothesis that the redox activity of APE1 is 
critical for EMT in EGFR- TKI- resistant NSCLC cells.
F I G U R E  4  Manipulations of APE1 
regulate the EMT process. The EMT 
markers in both cell lines with different 
APE1 status were measured by the epithelial 
marker E- cadherin or the mesenchymal 
marker vimentin using Western blot 
(A), phase contrast microscopy (B), and 
immunofluorescent staining (C). Following 
knockdown of APE1 in HCC827/IR and 
PC- 9/ER cells via siRNA transfection, 
the expression of E- cadherin, vimentin, 
and APE1 was determined by Western 
blot (D). Following overexpression of 
APE1 in EGFR- TKI- sensitive cells via 
lentiviral particles, relative expression 
levels of E- cadherin, vimentin, and APE1 
were determined by Western blot (E). 
Representative images or blots from at least 
three individual experimental repeats are 
shown in this figure
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3.6 | APE1 is elevated in T790M- negative 
EGFR- TKI- resistant patients
To test the proposed mechanisms determined from in vitro 
cell models, we compared the APE1 protein levels in pre- 
and post- treatment biopsy tissue of two patients receiving 
rebiopsy after progression and following treatment with 
first- generation EGFR- TKIs. Tumor tissue from Patient #1 
was initially characterized with an L858R mutation when di-
agnosed with left lung adenocarcinoma, then gefitinib was 
given at 250 mg, po., qd. After 10.8 months following the 
first gefitinib dose, disease progression in the left lung was 
confirmed by CT scan. Tumor tissue from Patient #2 was ini-
tially tested and characterized as an exon 19 deletion when 
diagnosed with left lung adenocarcinoma. Erlotinib was then 
given at 150 mg, po., qd. After 20.3 months following the 
first erlotinib dose, disease progression to the brain was con-
firmed by an MRI scan. Both patients underwent rebiopsy by 
core needle at disease progression and both tumors were de-
termined to be T790M negative by the Cobas method. APE1 
and EMT biomarkers, including E- cadherin and vimentin 
were tested using IHC assay. As shown in Figure 8, APE1 
was elevated in the rebiopsy tissue of both patients compared 
with the pretreatment tissue. In agreement with APE1 level, 
vimentin was upregulated in the rebiopsy tissue whereas E- 
cadherin was downregulated. This pilot clinical study further 
confirmed our in vitro results, strongly suggesting that APE1 
could be an emerging key player in EGFR- TKI responsive-
ness through regulating EMT.
4 |  DISCUSSION
While EGFR- TKIs significantly improve the survival and qual-
ity of life in advanced NSCLC patients carrying EGFR muta-
tions, acquired resistance to these inhibitors limits their clinical 
benefit, thus creating challenges for treatment and manage-
ment. In the current study, we describe a novel and pivotal role 
for APE1 in EGFR- TKI resistance, which suggests that APE1 
expression could predict the therapeutic effect of EGFR- TKI 
treatment. We further demonstrated that, through its redox reg-
ulation of TGF- β, APE1 plays a role in the control of EMT and 
mediation of EGFR- TKI resistance. The APE1 redox inhibitor 
E3330 restored sensitivity to EGFR- TKIs in established resist-
ant cell lines, further implying efficacy for therapeutic combi-
nations of specific APE1 inhibitors and EGFR- TKIs with the 
potential of restoring their clinical benefit.
The sensitizing effects of APE1 on other conventional 
anticancer agents, including chemotherapeutic drugs and ir-
radiation, have been observed previously.21–23 Both chemo-
therapeutic agents, such as MMS, and irradiation, such as 
X- rays, generate numerous DNA lesions that, if unrepaired, 
cause cell death. Thus, the mechanistic explanations of pre-
vious reports regarding the sensitizing effects of APE1 on 
F I G U R E  5  APE1 regulates EMT 
through TGF- β signaling. TGF- β secretion 
level was evaluated by ELISA in EGFR- 
TKI- resistant cell lines and their parental 
sensitive cells (A). The 24- hour cell- free 
supernatants of tissue culture from PC- 9 
with or without APE1 overexpression and 
PC- 9/ER with or without APE1 knockdown 
were collected 48 h post- transfection or 
infection and then evaluated by ELISA 
(B and C). Recombinant TGF- β protein 
was added to the culture medium of APE1 
knockdown PC- 9/ER cells, treated with 
increasing concentrations of gefitinib, and 
then, the cytotoxicity of EGFR- TKI was 
determined by CCK8 assay (D). To exclude 
the impact of APE1 manipulation on cell 
growth, various gefitinib dose treatments 
of each group have been normalized to 
the readout of 0 μmol/L (DMSO only) 
treatment. Mean values of at least three 
individual experimental repeats are shown 
as the mean ± SD. * indicates a statistically 
significant difference when compared with 
the same treatment dose as its parental cell 
(P < 0.01)
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anticancer agents were largely correlated with its essential 
activity in DNA repair. However, EGFR- TKIs, as the first 
type of targeted drugs in NSCLC, are specifically targeted 
to driver mutations of EGFR and inhibit their prosurvival 
activity, an effect which lacks a direct link to DNA damage 
and repair. As seen in our experiments, a potent DNA repair 
activity inhibitor of APE1, inhibitor III, failed to restore the 
sensitivity to EGFR- TKI, further supporting our hypothesis. 
Our intriguing and novel observation links, for the first time, 
the redox activity of APE1 with acquired resistance to EGFR- 
TKIs, which has potentially important clinical significance. 
Despite the controversies, many laboratories are currently 
working on the development of redox inhibitors of APE1, in-
cluding a derivate of E3330, APX3330 which is now in phase 
II clinical trials for pancreatic cancer and hematopoietic ma-
lignancies (via personal communication). With respect to 
these ongoing trials, the clinical use of APE1 redox inhibitors 
is not only reasonable but also feasible in the near future to 
reverse, or at least attenuate, resistance to the EGFR- TKIs.
Apart from the impact of the initial response to DNA 
damaging agents, APE1 levels have no impact on the initial 
response to EGFR- TKIs.24 However, elevated APE1 levels 
in pretreatment tissue showed a significant inverse correla-
tion with the duration of the response; in other words, the 
speed of acquired resistance development increases with el-
evated APE1 levels. We consider this pattern to be related to 
the onset of EMT initiation where APE1 plays a pivotal role. 
We recently discovered that APE1 protein is also present in 
human serum and, more importantly, is elevated in NSCLC 
patients, and correlates with platinum- containing chemo-
therapy responses. When tracing serum APE1 throughout 
treatment, APE1 levels change during chemotherapy and 
reflect therapeutic outcomes.25 Based on this observation, 
we initiated a trial to monitor changes in serum APE1 lev-
els during EGFR- TKI treatment. If a correlation between 
serum APE1 level and EGFR- TKI response can be observed 
prior to the actual imaging progression, we could predict 
resistance events and prophylactically add APE1 inhibitors 
or other possible interventions by real- time monitoring.
To the best of our knowledge, this is the first study con-
firming that APE1 exerts a regulatory function in EMT. 
High APE1 expression in tumor tissue has been associated 
with advanced stage, poorer prognosis, metastasis, and drug 
resistance according to clinical data.26 Several models have 
been proposed accounting for APE1′s functions in promot-
ing the malignant phenotype of different cancers. For the 
first time, APE1 has been associated with an important cel-
lular process, EMT, which could account for the progression, 
particularly the metastasis and drug resistance of certain 
epithelial cancers.27 The newly established correlation be-
tween APE1 and EMT provides a plausible explanation for 
the malignant phenotypes associated with overexpression of 
F I G U R E  6  The redox activity of 
APE1 in EGFR- TKI response and EMT. 
HCC827/IR and PC- 9/ER cells were treated 
with increasing concentrations of gefitinib 
and APE1 inhibitors, including 10 μmol/L 
inhibitor III (inhibits endonuclease activity) 
and 10 μmol/L E3330 (inhibits redox 
activity), with subsequent determination 
of the cytotoxicity of EGFR- TKI by CCK8 
assay (A and B). To exclude the impact of 
APE1 manipulation on cell growth, various 
gefitinib dose treatments of each group have 
been normalized to the readout of 0 μmol/L 
(DMSO only) treatment. The EMT markers 
were determined by Western blot in cells 
treated with each inhibitor at 10 μmol/L 
(C). The mean values of at least three 
individual experimental repeats are shown 
as the mean ± SD, * Statistically significant 
difference when compared with the DMSO 
group at the same gefitinib dose (P < 0.05)
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APE1. With respect to the possible relation between EMT 
and cancer stem cells (CSCs), APE1 might also play a role 
in CSC maintenance, which has been supported by some 
circumstantial evidence.28 The causal functional link exist-
ing between APE1 and CSC, as well as its relationship with 
the EMT, should be further investigated considering that the 
alterations of these stem cells are responsible for EGFR- TKI 
resistance.29 To further substantiate the important role of 
APE1 in EMT, we discovered that E3330 can effectively 
suppress the EMT process and the peritoneal and liver me-
tastasis of cervical cancer cells in nude mice which suggests 
that APE1 plays a pivotal role in tumor metastasis through 
promoting EMT (unpublished data).
Our current data provide evidence that APE1 regulates 
TGF- β secretion and that increased APE1 is associated with 
increased TGF- β secretion, which initiates EMT and impedes 
cellular response to EGFR- TKIs. It is noteworthy that Sakai 
et al30 reported previously that TGF- β mRNA was elevated in 
APE1 knockdown lung carcinoma cell line A549 and cervi-
cal cancer cell line HeLa. They also linked the downregula-
tion of APE1 to increased cellular motility. However, clinical 
studies have shown that higher APE1 expression is associated 
with more advanced stages and poorer prognosis of cancer. 
This single report contradicted previous clinical evidence 
that overexpression of APE1 is correlated with malignancy of 
cancer and thus should be further evaluated. As a very com-
plex process, the molecules and mechanisms involved in reg-
ulating EMT are not yet fully identified. Transcription factors 
including Snail, Slug, and ZEB1/2 have been shown to be 
important for reprogramming of the gene expression profile 
F I G U R E  7  APE1 promotes the metastatic potential of xenograft lung cancer cells in nude mice. One million HCC827/IR cells were 
inoculated subcutaneously into nude mice which were then treated with icotinib at 0 mg/kg, 70 mg/kg alone, and 70 mg/kg together with E3330 
at 25 mg/kg (n = 6 mice or 12 xenografts/group). Xenograft growth was measured in two dimensions, and volume was recorded (tumor size 
(mm3) = (maximum diameter ×minimum diameter2)/2) (A). After daily treatment for 12 d, the nude mice were sacrificed, and histologically intact 
xenografts were collected. The expression of APE1, E- cadherin, and vimentin in the xenograft extracts was detected by Western blot (B). EMT 
analyses of tissue slides were performed via IHC staining of E- cadherin and vimentin (C). The mean values of the 12 xenografts of each group are 
shown as the mean ± SD, * Statistically significant difference when compared with the control group (P < 0.05)
   | 13YANG et Al.
during EMT. One might wonder whether other transcription 
factors previously reported to be associated with APE1 redox 
activity, such as STAT3 and HIF- 1, might participate in the 
process of EMT reversion induced by APE1 inhibition.31,32 
We tested both STAT3 and HIF- 1 DNA binding activities 
in EGFR- TKI- resistant cell lines and their parental lines via 
electrophoretic mobility shift assay (EMSA) and found that 
the DNA binding activity of both TFs retains similar levels in 
both EGFR- TKI- resistant and EGFR- TKI- sensitive cell lines. 
We did confirm that APE1 manipulation by shRNA or overex-
pression vectors can affect the DNA binding activities of both 
TFs (Figure S3). These data suggest that APE1 expression 
regulates the activities of both TFs but they probably have no 
significant roles in EGFR- TKI resistance in our current set-
ting. Considering the transcriptional regulatory role of APE1, 
it is possible that APE1 may also directly regulate other key 
transcription factors that promote EMT. Additional work in 
our laboratory is underway to investigate this possibility.
Taken together, the current study reveals a significant 
role of APE1 in EGFR- TKI resistance via novel regulatory 
effects on EMT in NSCLC and provides evidence support-
ing the involvement of APE1 in a malignant progression 
through EMT. More importantly, this study suggests the 
possible predictive role of APE1 levels in tissue or serum 
for EGFR- TKI responsiveness and sheds light on the future 
clinical utility of APE1 redox inhibitors to overcome EGFR- 
TKI resistance.
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